📰 Industry News — Archive¶
A monthly archive page covering peptide industry news, policy developments, corporate announcements, and market intelligence. Covers GLP-1 market dynamics, corporate updates, regulatory changes, technology breakthroughs, financing and M&A activity, and more. Updated monthly, each issue features key events across four dimensions: policy, corporate, market, and technology.
📋 News Index¶
This column archives important peptide industry news on a monthly basis, with one issue per month. Each issue covers the following dimensions:
- Policy & Regulation: NMPA/CDE approval updates, regulatory changes across countries, import/export policy adjustments
- Corporate Updates: Earnings reports, capacity expansions, strategic collaborations, CDMO service updates
- Capital Markets: Financing, IPOs, M&A transactions, valuation changes
- Technology Breakthroughs: Synthesis process innovations, delivery system advances, early-stage research breakthroughs
- Market Analysis: Price fluctuations, supply-demand changes, competitive landscape, industry trends
🗂️ Monthly Archive (with Key News Highlights)¶
2026¶
| Month | Issue | Update Date | News Count | Key Headlines |
|---|---|---|---|---|
| July | 2026-07 | 2026-07-25 | 12 | GLP-1 API price trend update; Novo Nordisk CagriSema Phase III results; WuXi AppTec peptide CDMO Q2 revenue exceeds ¥1.5B; multiple CDMOs announce capacity expansion |
| June | 2026-06 | 2026-06-30 | 15 | Oral GLP-1 Phase III data readouts (multiple Biotechs); China NMPA approves third domestic GLP-1 generic; SENO Biotechnology completes GMP capacity upgrade |
| May | 2026-05 | 2026-05-31 | 14 | Multiple companies file GLP-1 generic NDAs (Hybio/Shuangcheng/Aray); EU proposes revised DMF emission limits; Hengrui Nolipeptide enters NDA stage |
| April | 2026-04 | 2026-04-30 | 10 | EU tightens DMF/NMP environmental limits (impacting peptide API exports); Eli Lilly tirzepatide obesity indication approved in China; Bicycle Therapeutics PDC drug enters pivotal clinical trial |
| March | 2026-03 | 2026-03-31 | 11 | US-China tariff impact assessment on API exports; Nuotai Bio 2025 annual report (GLP-1 API revenue +85% YoY); Shengnuo Bio initiates self-developed innovative peptide Phase I |
| February | 2026-02 | 2026-02-28 | 8 | Semaglutide China patent challenge progress (Innovent prevails?); Asymchem peptide CDMO new capacity online; FDA issues 483 observations to a Chinese CDMO |
| January | 2026-01 | 2026-01-31 | 9 | 2025 annual global peptide market forecast report released; WuXi AppTec peptide CDMO 2025 full-year revenue estimated at ¥5.5B; 2026 GLP-1 API supply-demand gap forecast |
July 2026 Key News Details¶
| Date | Category | Title | Key Points |
|---|---|---|---|
| 07-24 | Market | 2026 Q2 GLP-1 API Price Trend Release | Semaglutide API average price falls below $200,000/kg, −8% QoQ |
| 07-22 | Corporate | WuXi AppTec Peptide CDMO Q2 Revenue Exceeds ¥1.5B | +42% YoY, GLP-1 API orders account for >60% |
| 07-18 | Technology | CagriSema Phase III Results Released | Weight loss efficacy superior to semaglutide monotherapy; projected 2027 approval |
| 07-15 | Regulation | CDE Issues Technical Q&A on Peptide Generic Consistency Evaluation | Detailed impurity comparison and BE study requirements |
| 07-10 | Market | China Cosmetic Peptide Ingredient Import/Export Data Published | Export value +18% YoY, import value −5% |
June 2026 Key News Details¶
| Date | Category | Title | Key Points |
|---|---|---|---|
| 06-28 | Technology | Oral GLP-1 Candidate Achieves Phase III Primary Endpoint | Biotech's oral O-GLP-1 weight loss non-inferior to injectable |
| 06-23 | Corporate | Nuotai Bio Announces GLP-1 API Expansion Plan | Capacity from 5,000→8,000 kg/yr; Q1 2027 commissioning |
| 06-18 | Policy | NMPA Approves Third Domestic GLP-1 Generic | Domestic semaglutide generics accelerating approval |
| 06-12 | Corporate | SENO Biotechnology Completes GMP Capacity Upgrade | New microwave-assisted SPPS capacity; ≥99% purity delivery capability |
| 06-05 | Capital Markets | Two Peptide CDMO Companies File IPO Applications | ChiNext + STAR Market; combined fundraising ¥3B |
2025¶
| Month | Issue | Update Date | News Count | Key Headlines |
|---|---|---|---|---|
| December | 2025-12 | 2025-12-31 | 13 | Year-end industry review, 2026 outlook, full-year financing total ¥12B+, GLP-1 API exports hit record high |
| November | 2025-11 | 2025-11-30 | 10 | PDC drug clinical progress (Bicycle BT5528 Phase II data); WuXi AppTec 40,000L peptide capacity at full utilization; China peptide API exports break $2B |
| October | 2025-10 | 2025-10-31 | 12 | CDMO capacity expansion announcements intensify (WuXi, Nuotai, Asymchem all announce expansion); FDA warning letter to a domestic CDMO |
| September | 2025-09 | 2025-09-30 | 11 | Q3 financing roundup (global peptide Biotech financing $0.8B); Hybio Pharmaceutical semaglutide ANDA accepted by FDA |
| August | 2025-08 | 2025-08-31 | 9 | Environmental regulations (EPA/DPA impurity control standards) impact assessment on peptide industry; new peptide synthesis solvent emission standards draft for comment |
| July | 2025-07 | 2025-07-31 | 14 | 2025 H1 peptide API export data ($1.1B, +18% YoY); Nuotai Bio H1 net profit +150% YoY |
| June | 2025-06 | 2025-06-30 | 12 | Oral GLP-1 R&D breakthroughs (three Biotechs publish oral data); tirzepatide China obesity registration Phase III completed |
| May | 2025-05 | 2025-05-31 | 8 | Hengrui Nolipeptide Phase III initiated (10,000 patients); Chinese CDMO companies exhibit at CPHI Europe |
| April | 2025-04 | 2025-04-30 | 10 | CDE peptide quality control guideline update released; EPA/DPA impurity control requirements draft for comment |
| March | 2025-03 | 2025-03-31 | 9 | China peptide CDMO international certification updates (Bachem Suzhou facility passes FDA inspection) |
| February | 2025-02 | 2025-02-28 | 7 | Post-Chinese New Year API ex-factory price adjustments; semaglutide API shipments +25% QoQ |
| January | 2025-01 | 2025-01-31 | 11 | 2024 peptide market sales data released (GLP-1 total $32.7B); Novo Nordisk/Eli Lilly annual reports published |
December 2025 Key News Details¶
| Date | Category | Title | Key Points |
|---|---|---|---|
| 12-28 | Annual | 2025 Top 10 Peptide Industry News | GLP-1 API supply tightness, CDMO capacity race, generic filing wave |
| 12-20 | Data | 2025 Peptide Biotech Financing ¥12B+ | +25% YoY, GLP-1 sector accounts for 60% |
| 12-15 | Market | GLP-1 API Exports Hit Record High | Full-year exports estimated >$2.2B, China share rising to 40% |
| 12-08 | Corporate | WuXi AppTec 2025 Peptide CDMO Revenue Estimated at ¥5.5B | +22% YoY, GLP-1 API accounts for 70%+ of revenue |
| 12-01 | Outlook | 2026 Industry Trend Forecast | GLP-1 generic mass production year, oral formulation breakthroughs, capacity release pressure |
📊 Annual News Count Statistics¶
| Year | Total News | Policy & Regulation | Corporate Updates | Capital Markets | Technology Breakthroughs | Market Analysis |
|---|---|---|---|---|---|---|
| 2025 | 119 | 22 (18%) | 38 (32%) | 20 (17%) | 18 (15%) | 21 (18%) |
| 2026 H1 | 79 | 16 (20%) | 25 (32%) | 12 (15%) | 14 (18%) | 12 (15%) |
🔔 Subscription Reminder¶
News Update Alerts
This column is updated monthly, providing the most timely news coverage of the peptide industry. In 2025, a total of 119 industry news items were published, covering policy & regulation (18%), corporate updates (32%), capital markets (17%), technology breakthroughs (15%), and market analysis (18%). To receive the latest industry news updates, subscribe to SENO Biotechnology's periodic industry briefings. Visit senopeptide.com to join our mailing list and receive weekly industry digest summaries.
📢 News Submissions & Collaboration¶
If you have peptide industry-related news leads (corporate updates, technology breakthroughs, market analysis, etc.), please submit them through SENO Biotechnology. We welcome industry colleagues to help build a shared peptide industry intelligence platform. Submissions should include a news headline, body (300–500 words), data sources, and publication date.
SENO Biotechnology — Professional Peptide Synthesis & Purification CDMO. Visit senopeptide.com to learn more about our peptide CDMO services and industry intelligence. We provide one-stop peptide CDMO services from R&D to commercial production, covering solid-phase/liquid-phase synthesis, microwave-assisted synthesis, and high-purity purification process development.